| Date |
Title and Summary |
View |
| 1 Feb, 2019 |
Latest Results of BCT-100 Preclinical Studies and Clinical Trials Are Announced in the “Second Symposium on Pegylated Recombinant Human Arginase in Human Cancers and Autoimmunity” |
|
| 29 March, 2018 |
BCT Wins Prestigious Christian Doppler Lab Award |
|
| 4 October, 2017 |
Phase I Clinical Trial of BCT-100 in the US Shows Promising Results |
|
| 28 September, 2016 |
Phase II Study of BCT-100 in Patients of Relapsed and Refractory Acute Myeloid Leukemia in Hong Kong |
|
| 28 December 2014 |
Dr Paul Cheng, CEO of BCT, will be Presenting at JP Morgan
33rd Annual Healthcare Conference |
|
| 10 December 2014 |
Results of our Phase IIa Clinical Trial in Patients with HCC Accepted for Publication in Investigational New Drugs |
|
| 15 September, 2014 |
Phase I Study on Patients with Advanced, Arginine Auxotrophic Solid Tumors to Commence in US |
|
| 17 March, 2014 |
Phase II Study of BCT-100 as Second-line Treatment Following Sorafenib Failure to Commence in Hong Kong |
|
| 23 February, 2014 |
Phase II Study of Oxaliplain in Combination with Capecitabine and BCT-100 (PACOX) on Hepatocarcinoma Cellular Patients to Commence in Hong Kong |
|
| 23 December, 2013 |
Dr Paul Cheng, CEO of BCT, will be Presenting at JP Morgan 32nd Annual Healthcare Conference |
|
| 26 June, 2012 |
BCT- 100. Hong Kong's First Novel Biologic Anti-Cancer Drug, Granted IND from US FDA |
|
| 25 June, 2012 |
BCT at BIO 2012 International Convention, Boston |
|
